Please login to the form below

Not currently logged in
Email:
Password:

Simon Lowth steps down as AZ’s CFO

Joins natural gas firm BG Group in same role

AstraZeneca-Simon-LowthAstraZeneca's chief financial officer Simon Lowth is set to leave the pharma company to take up a similar position at natural gas firm BG Group.

Lowth will step down in October after six years at the company, including a spell as interim CEO in 2012 following the departure of David Brennan.

AZ later hired Roche's former chief operating officer Pascal Soriot to fill the top job and he has since sought to rejuvenate the company's ailing research efforts and announced plans to move its global headquarters from London to Cambridge.

Commenting on Lowth's departure Soriot said: “Simon has made a significant and lasting contribution to AstraZeneca's success, helping put the company on a stronger footing for the future.

“Personally, I will miss our interactions and I would like to thank him for all his support over the last few months.”

Lowth succeeds interim chief financial officer Den Jones at BG Group, with this new role marking another path in a varied financial and business career, which includes his role as corporate strategy director at Scottish power from 2003 to 2007 prior to his time at AZ.

Lowth previously spent 15 years working for McKinsey & Company, including his most senior role as the director responsible for the UK industrial practice.

“BG Group is an outstanding company in a sector that I know well and I look forward to working with the team to build on its successes and deliver on the opportunities in this next stage of its evolution,” said Lowth.

AZ said a search for Lowth's successor is underway.

17th July 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics